Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 3, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.
Cash runway is approximately 32.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 3, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| November 15, 2028 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | Trial Milestone | Phase 2 |
Track BDTX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open BDTX in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 5, 2026 | Quarterly results filed (8-K) | Earnings | — |
| May 21, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| May 7, 2026 | Quarterly results filed (8-K) | Earnings | — |
| March 16, 2026 | Quarterly results filed (8-K) | Earnings | — |
| December 3, 2025 | Quarterly results filed (8-K) | Earnings | — |
| November 6, 2025 | Quarterly results filed (8-K) | Earnings | — |
| November 3, 2025 | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations | Trial Milestone | Phase 1/Phase 2 |
| August 7, 2025 | Quarterly results filed (8-K) | Earnings | — |
| May 12, 2025 | Quarterly results filed (8-K) | Earnings | — |
| September 2, 2022 | A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. | Trial Milestone | Phase 1 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.